Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT01902225 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
T-Cell Lymphoma
Cutaneous Lymphoma

Interventions

DRUG: Istodax
DRUG: Doxil

Sponsor

Weiyun Ai

Collaborators

[object Object]